A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors
Latest Information Update: 06 May 2024
At a glance
- Drugs Iobenguane (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPORE-3
- 25 Apr 2024 Status changed from recruiting to withdrawn prior to enrolment. (Azedra withdrawn from US market)
- 07 Feb 2023 Status changed from not yet recruiting to recruiting.
- 07 Jul 2022 Planned initiation date changed from 1 Jun 2022 to 1 Dec 2023.